The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel

British Journal of Clinical Pharmacology

Volumn 60, Issue 1, 2005, Pages 69-75

  Korhonen, Tuomas ^a,e   Tolonen, Ari ^b   Uusitalo, Jouko ^b   Lundgren, Stefan ^c   Jalonen, Jorma ^d   Laine, Kari ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Novamass Analytical Ltd   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF OULU   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

3 keto desogestrel; Cytochrome P450 (CYP) enzyme; Desogestrel; Drug interaction; Metabolism

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DESOGESTREL; ETONOGESTREL; FLUCONAZOLE; ITRACONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DESOGESTREL; FEMALE; GENOTYPE; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 21744432250     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02382.x     Document Type: Article

References (33)

1. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl 1): S7-S16.
2. Viinikka L, Ylikorkala O, Nummi S, Virkkunen P, Ranta T, Alapiessa U, Yihko R. Biological effects of a new and potent progestagen. A clinical study. Acta Endocrinol (Copenh) 1976; 83: 429-38.
3. Viinikka L. Metabolism of a new synthetic progestagen, Org 2969, by human liver in vitro. J Steroid Biochem 1979; 10: 353-7.
4. Madden S, Back DJ, Orme ML. Metabolism of the contraceptive steroid desogestrel by human liver in vitro. J Steroid Biochem 1990; 35: 281-8.
5. Gentile DM, Verhoeven CH, Shimada T, Back DJ. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998; 287: 975-82.
6. Madden S, Back DJ, Martin CA, Orme ML. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol 1989; 27: 295-9.
7. Viinikka L, Ylikorkala O, Vihko R, Wijnand HP, Booij M, van der Veen F. Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. Pharmacokinetics after an oral dose. Eur J Clin Pharmacol 1979; 15: 349-55.
8. Hasenack HG, Bosch AM, Kaar K. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel. Contraception 1986; 33: 591-6.
9. Back DJ, Grimmer SF, Shenoy N, Orme ML. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception 1987; 35: 619-26.
10. Bergink W, Assendorp R, Kloosterboer L, van Lier W, Voortman G, Qvist I. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. Am J Obstet Gynecol 1990; 163: 2132-7.
11. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
12. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
13. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
14. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH. cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
15. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-8.
16. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7.
17. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjogvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-97.
18. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31.
19. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
20. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29: 1051-6.
21. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
22. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23-9.
23. Kunze KL, Wienkers LC, Thummel KE, Trager WF, Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414-21.
24. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-5.
25. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-8.
26. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445-9.
27. Wienkers LC, Wurden Q, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996; 24: 610-4.
28. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36: 783-91.
29. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511-6.
30. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
31. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14: 143-9.
32. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003; 56: 683-90.
33. Masimirembwa CM, Hasler JA, Johansson I. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995; 48: 35-8.